Brand names: MEKTOVI
Binimetinib is indicated for:
Unresectable or metastatic melanoma with a BRAF V600 mutation
Irrespective of gender only Adults (18 years old or older)
Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 90 mg divided into 2 equal doses
Active ingredient Binimetinib is contraindicated in the following cases: